Table 2:
Population Pharmacokinetic Estimates for Tenofovir Alafenamide (TAF)
| Parameter (units) | Final NONMEM Estimate | Median Bootstrap Estimate | Bootstrap 95% CI | %RSE |
|---|---|---|---|---|
| Ka (hr−1) | 2.08 | 2.03 | (1.57 – 2.46) | 23.6% |
| VTAF (L)* | 75.0 | 75.0 | -- | -- |
| K20 (hr−1) | 1.20 | 1.23 | (1.16 – 1.45) | 5.43% |
| K23 (hr−1) | 0.0489 | 0.0479 | (0.0000153 – 0.090) | 28.8% |
| VTFV (L)* | 2000 | 2000 | -- | -- |
| K30 (hr−1) | 0.0130 | 0.0124 | (0.00000395 – 0.0337) | 36.0% |
| K24 (hr−1) | 1.07 | 1.08 | (0.795 – 1.72) | 12.9% |
| K40 (hr−1) | 0.00215 | 0.00230 | (0.000101 – 0.0109) | 55.0% |
| K25 (hr−1) | 0.000943 | 0.000963 | (0.000692 – 0.00213) | 68.2% |
| K50 (hr−1) | 0.762 | 0.625 | (0.602 – 1.13) | 21.8% |
| K46 (hr−1) | 0.00952 | 0.00947 | (0.00145 – 0.0135) | 17.0% |
| K56 (hr−1) | 0.000256 | 0.000523 | (0.0000102 – 0.00716) | 643% |
| K60 (hr−1) | 1.97 | 1.98 | (0.244 – 3.21) | 20.2% |
| ω on K30 (%CV) | 74.5% | 67.9% | (20.9% - 94.3%) | 29.4% |
| ω on K40 (%CV) | 120% | 113% | (16.7% - 185%) | 55.9% |
| ω on K50 (%CV) | 38.3% | 48.91% | (0.0976% - 48.92%) | 23.3% |
| ω on K60 (%CV) | 85.4% | 84.5% | (3.15% - 118%) | 40.4% |
| ο on TAF BP (%CV) | 86.1% | 95.6% | (55.7% - 150%) | 184% |
| ο on PBMC (%CV) | 56.0% | 52.6% | (32.5% - 79.3%) | 28.3% |
| ο on TVF BP (%CV) | 10.9% | 10.9% | (8.16% - 12.1%) | 9.87% |
| ο on TAFSP(%CV) | 51.7% | 55.4% | (32.8% - 66.2%) | 995% |
| ο on TVF SP(%CV) | 48.6% | 44.6% | (26.9% - 69.8%) | 30.4% |
| ο on SMC (%CV) | Not Applicable | |||
*
Fixed Parameter
95% CI - 95% Confidence Interval of bootstrap estimate
%RSE – Relative Standard Error in Percentage Terms
ω – Interindividual Variability
ο – Residual Variability
%CV - Coefficient of Variation in Percentage Terms